Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176361 | 0.90 | BRD4 (0.56) | HTR6BRD4 | |
| SCHEMBL4158099 | 0.88 | BRD4 (0.54) | HTR6PTGDR2BRD4AURKAAURKB | |
| SCHEMBL4155597 | 0.86 | HTR6 (0.45) | HTR6PTGDR2BRD4BRAF | |
| SCHEMBL4160914 | 0.85 | PTGDR2 (0.45) | HTR6PTGDR2BRD4ITKAURKA | |
| SCHEMBL3253600 | 0.84 | BRD4 (0.46) | HTR6PTGDR2BRD4ITKAURKA | |
| SCHEMBL4166792 | 0.84 | PTGDR2 (0.41) | HTR6PTGDR2BRD4BRAF | |
| SCHEMBL4157748 | 0.83 | BRD4 (0.57) | HTR6PTGDR2BRD4 | |
| SCHEMBL4159606 | 0.83 | SPR (0.46) | HTR6BRD4 | |
| SCHEMBL4157612 | 0.83 | BRD4 (0.58) | BRD4AURKAAURKBBRAFSGK1 | |
| SCHEMBL4163279 | 0.83 | PKM (0.48) | HTR6BRD4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | HTR6 4018/4885PTGDR2 789/4885BRD4 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.